Go Back
TG THERAPEUTICS, INC. reports $39.2 million Q1 loss
By USInMinutes - May 01, 2023, 09:12 AM ET
Last Updated - Jul 18, 2023, 03:46 PM EDT
The company generated $7.80 million in quarterly revenue
TG THERAPEUTICS, INC. [TGTX] has reported fiscal Q1 loss of $39.20 million.
On a per-share basis, the DE based company said its diluted earnings are $0.28.
The Pharmaceutical Preparations firm posted revenue of $7.80 million in this period.
Also Read:
- TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
- TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from ...
- TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of ...
- TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the ...
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News